Busulfan-Melphalan Superior as Myeloablative Tx for High-Risk Neuroblastoma
June 17, 2011|Hematology and Oncology
Author and Disclosure Information
FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY
CEM was associated with higher rates of grade 3/4 infectious, gastrointestinal, and renal adverse effects, and ototoxicity. BUMEL was associated with a higher rate of grade 3/4 veno-occlusive disease; patients in the trial did not receive prophylactic anticoagulation with defibrotide, she noted.
Dr. Ladenstein and Dr. Park said they had no disclosures. The intravenous form of busulfan was provided by Pierre Fabre Médicament Oncology.
